Spectrum Pharmaceuticals Out-Licenses Rights for Greater China To CASI Pharmaceuticals For Three Of Its Drugs
September 18, 2014 at 07:02 AM EDT
Spectrum receives a 19.99% stake (pre-transaction) in CASI, a NASDAQ-listed, oncology-focused Company with expertise and focus on ...
